[Use of PGF2 alpha to induce abortion in patients with risk factors in first and second thirds of gravidity (author's transl)].
Reported in this paper is the use of PGF2 alpha to induce legal abortion in 43 patients with uterine risk factors (Group 1) or with general diseases manifest before (Group 2). The abortions were induced between the eighth and 24th weeks of pregnancy. PGF2 alpha was applied extra-amniotically, intra-amniotically or by combined approach, that is intra-amniotic or intravenous with extra-amniotic. - Twenty-seven women were included in Group 1, and in 25 of them pregnancy was disrupted without any complications. Complete expulsion of foetus and placenta, caused by rupture in the posterior labium of the os uteri, occurred to one of the patients with myomatous uterus. Acute ascension developed in another patient, three days from the intervention. - Group 2 was composed of 16 patients. Induced abortion was without any complications in 15, while one patient with psychosomatic epilepsy had an epileptic fit. Her pregnancy had to be terminated by hysterotomy. - The use of PGF2 alpha is considered an effective method to induce abortion in patients with risk factors.
D000032:Abortion, Therapeutic; D000650:Amnion; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D007275:Injections, Intravenous; D011247:Pregnancy; D011248:Pregnancy Complications / Q000601:surgery; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*; D012306:Risk
D011461:Prostaglandins F, Synthetic
Abortinduktion mit PGF 2 alpha im ersten und zweiten Trimester der Gravidität bei Patientinnen mit Risikofaktoren.